Acrivon Therapeutics, Inc.
NGM: ACRVLive Quote
📈 ZcoreAI Score
Our AI model analyzes Acrivon Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get ACRV Z-Score →About Acrivon Therapeutics, Inc.
Healthcare
Biotechnology
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
📊 Fundamental Analysis
Acrivon Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -53.9%, which indicates that capital utilization is currently under pressure.
At a current price of $1.56, ACRV currently sits at the 20th percentile of its 52-week range (Range: $1.05 - $3.56).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$60.44M
Trailing P/E
--
Forward P/E
-0.84
Beta (5Y)
1.74
52W High
$3.56
52W Low
$1.05
Avg Volume
864K
Day High
Day Low